Facebook X (Twitter) Instagram
    Facebook Instagram Threads
    Global BiodefenseGlobal Biodefense
    Subscribe
    • Featured News
    • Funding
    • Directory
    • Jobs
    • Events
    Global BiodefenseGlobal Biodefense
    Public Health

    Coronavirus Can Cause Lasting Lung Damage – But the Effects May Ease Over Time

    By Shanya Sivakumaran, Gwyneth Davies, and Mohammad Al SallakhJune 30, 2020
    Photo by Antonio Guillem / Shutterstock
    Share
    Facebook LinkedIn Reddit Email

    We know a lot about the symptoms of severe COVID-19, but relatively little about what happens after someone recovers. Could there be long-term effects? Let’s look at what we know so far about the effect of COVID-19 on the body – particularly the lungs – and the potential for lasting damage.

    The lungs are the organ most commonly affected by COVID-19, with a spectrum of severe effects. One is pneumonia, where inflammation causes the small air sacs that make up the lung to fill with fluid. In COVID-19, pneumonia tends to affect both lungs. If large parts of the lungs are affected, people struggle to absorb enough oxygen and are admitted to hospital.

    Another severe effect is acute respiratory distress syndrome (ARDS) – also known as “wet lung”. This sees severe inflammation spread quickly throughout the lungs. People who develop this may need mechanical ventilation in an intensive care unit, sometimes for a prolonged period.

    COVID-19 has a further, unusual effect on the body. Compared to other respiratory viruses, it causes marked clotting in the small blood vessels of the lungs and other organs.

    How the Virus Damages the Lungs

    Although the lungs can recover from severe COVID-19, they can also sustain longer-term damage of varying severity.

    The SARS-CoV-2 virus enters the cells of the airway through the angiotensin-converting enzyme 2 (ACE2) receptor, a molecule that connects the inside of our cells to the outside via the cell membrane. When this happens, some people react to the virus’s presence by producing an intense immune response, known as a “cytokine storm”, along with increased blood clotting, all of which leads to damage to lung cells.

    Being on a ventilator – which may be necessary with ARDS – can also cause cell damage. Kiryl Lis/Shutterstock

    The body replaces cells damaged by the virus with scar tissue, which is thick and stiff. This can result in a condition called “pulmonary fibrosis”, which has been seen in people with COVID-19 and is probably more likely to develop if the lungs are severely affected by the infection. The condition can make people breathless doing activities that they would usually manage without difficulty. Drugs that reduce scarring may have a role in preventing it.

    We don’t yet know what the impact of pulmonary fibrosis is after infection, but it may lead to long-term symptoms and a progressive fall in lung function. That’s why it’s important to watch out for the condition in people who suffer from severe COVID-19.

    However, we can look at other coronaviruses – severe acute respiratory syndrome (Sars) and Middle East respiratory syndrome (Mers) – to try to predict long-term outcomes.

    We know that Sars can cause pulmonary fibrosis, and a large analysis of Sars and Mers patients showed weakened lung function and exercise capability in some survivors up to six months after hospital discharge. However, a 15-year follow-up of patients showed improvement in lung function and less damage visible on CT scans over time. An early study of people recovering from COVID-19 found that such damage also improves in the first few weeks after discharge from hospital.

    What About Other Organs?

    COVID-19 may also cause illness in other parts of the body, ranging from several weeks of non-specific symptoms to impairment of the kidneys, heart, gastrointestinal tract, nervous system and clotting system. Some effects could be partly caused by clots forming in the small blood vessels supplying these organs. There’s also likely to be an impact on mental health.

    Just as important is the impact on a person’s general fitness. People needing mechanical ventilation for a long time lose a significant degree of muscle mass, leaving them weak even after their lungs have recovered.

    People with limited reserves to begin with (such as older people) can become deconditioned even after “mild” COVID-19. This may reduce their ability to live independently, so it has important implications for demand on rehabilitation and social care services.

    Widespread persistent lung damage could mean more people using medical oxygen at home. Chaikom/Shutterstock

    We are still only six months beyond the first emergence of COVID-19, so it’s too early to tell what the extent of any long-term impacts will be. There are still many questions. Who is most at risk of long-term effects following COVID-19? And what could prevent these? COVIDENCE UK is a research study looking at these questions, and is recruiting adults who both have and haven’t had COVID-19 to try to find answers.

    While the vast majority who contract COVID-19 will make a full recovery, we’re likely to see more people with pulmonary fibrosis or persistent lung damage following ARDS caused by COVID-19. Many will be severely debilitated for some time following severe infection, and some will need home oxygen. Meeting such people’s longer-term health and care needs will pose a significant challenge.

    ABOUT THE AUTHORS

    Shanya Sivakumaran, Clinical Research Fellow in Respiratory Medicine, Swansea University; Gwyneth Davies, Professor of Respiratory Medicine, Swansea University, and Mohammad Al Sallakh, Research Officer in Asthma, Swansea University. This article is courtesy of The Conversation.

    Coronavirus COVID-19 Editor Pick SARS-CoV-2
    Share. Facebook LinkedIn Reddit Email
    Previous ArticleResearchers Identify Multiple Molecules that Shut Down SARS-Cov-2 Polymerase Reaction
    Next Article The U.S. Isn’t In a Second Wave of Coronavirus – the First Wave Never Ended

    Related Stories

    EPA Developing AMR Risk Framework for Antibacterial and Antifungal Pesticides

    September 29, 2023

    Provide Feedback on Federal DURC Biosafety Oversight of Potential Pandemic Pathogens

    September 24, 2023

    Committee to Examine Transmission and Geographic Spread of Chronic Wasting Disease

    September 24, 2023

    New Method Improves Quantification of Ricin in Complex Matrices

    September 20, 2023
    News Scan

    Biodefense Headlines – 19 September 2023

    News Scan September 19, 2023

    News highlights on health security threats and countermeasures curated by Global Biodefense This week’s selections include a global survey of gain-of-function research; funding of an mRNA mpox vaccine; Nipah virus outbreak in India; field detection of threat agents with acoustic…

    Upcoming Events

    Oct 3
    Virtual Event Virtual Event
    October 3 - October 5

    OneLab Summit 2023

    Oct 3
    Virtual Event Virtual Event
    12:00 pm - 2:00 pm EDT

    Public-Private Partnerships to Distribute, Dispense, and Administer Medical Countermeasures

    Oct 4
    Virtual Event Virtual Event
    10:00 am - 2:00 pm EDT

    Tunneling Nanotubes and Intracellular Protrusions Workshop

    Oct 12
    Virtual Event Virtual Event
    12:00 pm - 2:00 pm EDT

    Public-Private Partnerships for Acceptance and Uptake of Medical Countermeasures

    View Calendar

    Subscribe to Global Biodefense

    Get the latest news on pathogens and preparedness

    © 2023 Stemar Media Group LLC
    • About
    • Contact
    • Privacy
    • Subscribe

    Type above and press Enter to search. Press Esc to cancel.

    We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are okay with it.OkPrivacy policy